Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals

{ 'indexed': {'date-parts': [[2022, 5, 6]], 'date-time': '2022-05-06T09:42:20Z', 'timestamp': 1651830140646}, 'reference-count': 45, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T00:00:00Z', 'timestamp': 1651363200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 5]]}, 'DOI': '10.1016/j.ajg.2022.04.005', 'type': 'journal-article', 'created': {'date-parts': [[2022, 5, 6]], 'date-time': '2022-05-06T09:17:16Z', 'timestamp': 1651828636000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for ' 'COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals', 'prefix': '10.1016', 'author': [ {'given': 'Mohamed A.', 'family': 'Medhat', 'sequence': 'first', 'affiliation': []}, {'given': 'Mohamed', 'family': 'El-Kassas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Haidi', 'family': 'Karam-Allah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmed', 'family': 'Al Shafie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sherief', 'family': 'Abd-Elsalam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ehab', 'family': 'Moustafa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sahar M.', 'family': 'Hassany', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marwa', 'family': 'Salama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohamed S.', 'family': 'Abd Elghafar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hamdy', 'family': 'Sayed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohamed', 'family': 'Badr', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dalia T.', 'family': 'Kamal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmed', 'family': 'Shamseldeen', 'sequence': 'additional', 'affiliation': []}, {'given': "Ashima'a", 'family': 'Ossimi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Inas', 'family': 'Moaz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hossam', 'family': 'El-deen Esmael', 'sequence': 'additional', 'affiliation': []}, {'given': 'Azza M.', 'family': 'Ezz Eldin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sameera', 'family': 'Ezzat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hossam', 'family': 'Abdelghaffar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khaled', 'family': 'Abdelghaffar', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '3', 'key': '10.1016/j.ajg.2022.04.005_b0005', 'doi-asserted-by': 'crossref', 'first-page': '186', 'DOI': '10.3390/pathogens9030186', 'article-title': 'Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light ' 'of past human coronavirus outbreaks', 'volume': '9', 'author': 'Ashour', 'year': '2020', 'journal-title': 'Pathogens'}, { 'key': '10.1016/j.ajg.2022.04.005_b0010', 'doi-asserted-by': 'crossref', 'unstructured': 'Shi Y, Wang G, Cai X-p, Deng J-w, Zheng L, Zhu H-h, et al. An overview ' 'of COVID-19. Journal of Zhejiang University Science B 2020:1.', 'DOI': '10.1631/jzus.B2000083'}, { 'key': '10.1016/j.ajg.2022.04.005_b0015', 'unstructured': 'WHO. ' 'Global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments ' '2020.'}, { 'issue': '1', 'key': '10.1016/j.ajg.2022.04.005_b0020', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s13063-020-04988-7', 'article-title': 'The efficacy and safety of Ivermectin in patients with mild and ' 'moderate COVID-19: A structured summary of a study protocol for a ' 'randomized controlled trial', 'volume': '22', 'author': 'Hosseini', 'year': '2021', 'journal-title': 'Trials'}, { 'issue': '8', 'key': '10.1016/j.ajg.2022.04.005_b0025', 'doi-asserted-by': 'crossref', 'first-page': '707', 'DOI': '10.1001/jama.2020.0757', 'article-title': 'Coronavirus infections—more than just the common cold', 'volume': '323', 'author': 'Paules', 'year': '2020', 'journal-title': 'Jama'}, { 'key': '10.1016/j.ajg.2022.04.005_b0030', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1038/s41467-019-10280-3', 'article-title': 'Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 ' 'co-factors', 'volume': '10', 'author': 'Kirchdoerfer', 'year': '2019', 'journal-title': 'Nature communications'}, { 'issue': '7', 'key': '10.1016/j.ajg.2022.04.005_b0035', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'volume': '93', 'author': 'FURUTA', 'year': '2017', 'journal-title': 'Proceedings of the Japan Academy, Series B'}, { 'issue': '7594', 'key': '10.1016/j.ajg.2022.04.005_b0040', 'doi-asserted-by': 'crossref', 'first-page': '381', 'DOI': '10.1038/nature17180', 'article-title': 'Therapeutic efficacy of the small molecule GS-5734 against Ebola virus ' 'in rhesus monkeys', 'volume': '531', 'author': 'Warren', 'year': '2016', 'journal-title': 'Nature'}, { 'key': '10.1016/j.ajg.2022.04.005_b0045', 'doi-asserted-by': 'crossref', 'unstructured': 'Ju J, Kumar S, Li X, Jockusch S, Russo JJ. Nucleotide Analogues as ' 'Inhibitors of Viral Polymerases. bioRxiv 2020:2020.2001.2030.927574.', 'DOI': '10.1101/2020.01.30.927574'}, { 'key': '10.1016/j.ajg.2022.04.005_b0050', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen Y, Yiu C, Wong K. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like ' 'protease (3CLpro) structure: virtual screening reveals velpatasvir, ' 'ledipasvir, and other drug repurposing candidates [version 1; peer ' 'review: 3 approved]. F1000Research 2020;9.', 'DOI': '10.12688/f1000research.22457.1'}, { 'key': '10.1016/j.ajg.2022.04.005_b0055', 'doi-asserted-by': 'crossref', 'first-page': '117592', 'DOI': '10.1016/j.lfs.2020.117592', 'article-title': 'Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against ' 'SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking ' 'study', 'volume': '253', 'author': 'Elfiky', 'year': '2020', 'journal-title': 'Life Sci'}, { 'issue': '1', 'key': '10.1016/j.ajg.2022.04.005_b0060', 'doi-asserted-by': 'crossref', 'first-page': '428', 'DOI': '10.1002/hep.26371', 'article-title': 'New horizons in hepatitis C antiviral therapy with direct-acting ' 'antivirals', 'volume': '58', 'author': 'Aghemo', 'year': '2013', 'journal-title': 'Hepatology'}, { 'issue': '38', 'key': '10.1016/j.ajg.2022.04.005_b0065', 'doi-asserted-by': 'crossref', 'first-page': '4330', 'DOI': '10.3748/wjg.v24.i38.4330', 'article-title': 'Towards hepatitis C virus elimination: Egyptian experience, ' 'achievements and limitations', 'volume': '24', 'author': 'Omran', 'year': '2018', 'journal-title': 'World journal of gastroenterology'}, { 'issue': '5', 'key': '10.1016/j.ajg.2022.04.005_b0070', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of ' 'potential drugs by computational methods', 'volume': '10', 'author': 'Wu', 'year': '2020', 'journal-title': 'Acta Pharmaceutica Sinica B'}, { 'issue': '3', 'key': '10.1016/j.ajg.2022.04.005_b0075', 'doi-asserted-by': 'crossref', 'first-page': '227', 'DOI': '10.1016/j.jiph.2016.04.001', 'article-title': 'Nitazoxanide, a new drug candidate for the treatment of Middle East ' 'respiratory syndrome coronavirus', 'volume': '9', 'author': 'Rossignol', 'year': '2016', 'journal-title': 'Journal of infection and public health'}, { 'key': '10.1016/j.ajg.2022.04.005_b0080', 'doi-asserted-by': 'crossref', 'first-page': '609', 'DOI': '10.1016/S1473-3099(14)70717-0', 'article-title': 'A randomized, double-blind, placebo controlled clinical trial of ' 'nitazoxanide in adults and adolescents with acute uncomplicated ' 'influenza', 'volume': '14', 'author': 'Haffizulla', 'year': '2014', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.ajg.2022.04.005_b0085', 'doi-asserted-by': 'crossref', 'unstructured': 'Rajoli RK, Pertinez H, Arshad U, Box H, Tatham L, Curley P, et al. Dose ' 'prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or ' 'chemoprophylaxis. medRxiv 2020.', 'DOI': '10.22541/au.158938595.50403411'}, { 'key': '10.1016/j.ajg.2022.04.005_b0090', 'unstructured': 'Organization WH. Therapeutics and COVID-19: living guideline, 24 ' 'September 2021: World Health Organization; 2021.'}, { 'key': '10.1016/j.ajg.2022.04.005_b0095', 'series-title': 'Therapeutics and COVID-19: living guideline', 'author': 'Organization', 'year': '2021'}, { 'key': '10.1016/j.ajg.2022.04.005_b0100', 'doi-asserted-by': 'crossref', 'unstructured': 'Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. ' 'The American-European Consensus Conference on ARDS. Definitions, ' 'mechanisms, relevant outcomes, and clinical trial coordination. American ' 'journal of respiratory and critical care medicine 1994;149:818-824.', 'DOI': '10.1164/ajrccm.149.3.7509706'}, { 'issue': '8', 'key': '10.1016/j.ajg.2022.04.005_b0105', 'doi-asserted-by': 'crossref', 'first-page': '801', 'DOI': '10.1001/jama.2016.0287', 'article-title': 'The third international consensus definitions for sepsis and septic ' 'shock (Sepsis-3)', 'volume': '315', 'author': 'Singer', 'year': '2016', 'journal-title': 'Jama'}, { 'issue': '29', 'key': '10.1016/j.ajg.2022.04.005_b0110', 'doi-asserted-by': 'crossref', 'first-page': '18356', 'DOI': '10.1021/acsomega.0c02096', 'article-title': 'Prediction of Small Molecule Inhibitors Targeting the Severe Acute ' 'Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase', 'volume': '5', 'author': 'Ahmad', 'year': '2020', 'journal-title': 'ACS omega'}, { 'key': '10.1016/j.ajg.2022.04.005_b0115', 'doi-asserted-by': 'crossref', 'article-title': 'Remdesivir for the treatment of Covid-19—preliminary report', 'author': 'Beigel', 'year': '2020', 'journal-title': 'The New England journal of medicine', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': '10.1016/j.ajg.2022.04.005_b0120', 'doi-asserted-by': 'crossref', 'article-title': 'Remdesivir in adults with severe COVID-19: a randomised, double-blind, ' 'placebo-controlled, multicentre trial', 'author': 'Wang', 'year': '2020', 'journal-title': 'The Lancet', 'DOI': '10.1016/S0140-6736(20)31022-9'}, { 'issue': '1', 'key': '10.1016/j.ajg.2022.04.005_b0125', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41598-020-73641-9', 'article-title': 'Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader ' 'than RNA terminated by Remdesivir', 'volume': '10', 'author': 'Jockusch', 'year': '2020', 'journal-title': 'Scientific reports'}, { 'key': '10.1016/j.ajg.2022.04.005_b0130', 'series-title': 'Efficacy and safety of sofosbuvir/ledipasvir in treatment of patients ' 'with COVID-19; A randomized clinical trial', 'first-page': '91', 'author': 'Nourian', 'year': '2020'}, { 'key': '10.1016/j.ajg.2022.04.005_b0135', 'doi-asserted-by': 'crossref', 'unstructured': 'Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, ' 'Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of ' 'COVID-19 outpatients: a double-blind, randomized controlled trial. ' 'Journal of Antimicrobial Chemotherapy 2020.', 'DOI': '10.1093/jac/dkaa501'}, { 'key': '10.1016/j.ajg.2022.04.005_b0140', 'doi-asserted-by': 'crossref', 'unstructured': 'Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et ' 'al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with ' 'severe COVID-19. Journal of Antimicrobial Chemotherapy ' '2020;75:3366-3372.', 'DOI': '10.1093/jac/dkaa331'}, { 'key': '10.1016/j.ajg.2022.04.005_b0145', 'doi-asserted-by': 'crossref', 'unstructured': 'Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri ' 'M, et al. Sofosbuvir and daclatasvir compared with standard of care in ' 'the treatment of patients admitted to hospital with moderate or severe ' 'coronavirus infection (COVID-19): a randomized controlled trial. Journal ' 'of Antimicrobial Chemotherapy 2020;75:3379-3385.', 'DOI': '10.1093/jac/dkaa334'}, { 'key': '10.1016/j.ajg.2022.04.005_b0150', 'doi-asserted-by': 'crossref', 'first-page': '94', 'DOI': '10.1016/j.antiviral.2014.07.014', 'article-title': 'Nitazoxanide: a first-in-class broad-spectrum antiviral agent', 'volume': '110', 'author': 'Rossignol', 'year': '2014', 'journal-title': 'Antiviral research'}, { 'issue': '5', 'key': '10.1016/j.ajg.2022.04.005_b0155', 'doi-asserted-by': 'crossref', 'first-page': 'e1002691', 'DOI': '10.1371/journal.ppat.1002691', 'article-title': 'Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and ' 'intracellular proliferation of Mycobacterium tuberculosis', 'volume': '8', 'author': 'Lam', 'year': '2012', 'journal-title': 'PLoS pathogens'}, { 'key': '10.1016/j.ajg.2022.04.005_b0160', 'article-title': 'Early use of nitazoxanide in mild Covid-19 disease: randomised, ' 'placebo-controlled trial', 'author': 'Rocco', 'year': '2020', 'journal-title': 'European Respiratory Journal'}, { 'issue': '5', 'key': '10.1016/j.ajg.2022.04.005_b0165', 'doi-asserted-by': 'crossref', 'first-page': '3176', 'DOI': '10.1002/jmv.26880', 'article-title': 'Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus ' 'zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19', 'volume': '93', 'author': 'Elalfy', 'year': '2021', 'journal-title': 'Journal of medical virology'}, { 'issue': '1', 'key': '10.1016/j.ajg.2022.04.005_b0170', 'doi-asserted-by': 'crossref', 'first-page': '105', 'DOI': '10.1016/j.medj.2020.04.001', 'article-title': 'Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients ' 'with mild/moderate COVID-19: an exploratory randomized controlled trial', 'volume': '1', 'author': 'Li', 'year': '2020', 'journal-title': 'Med'}, { 'key': '10.1016/j.ajg.2022.04.005_b0175', 'doi-asserted-by': 'crossref', 'article-title': 'A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe ' 'Covid-19', 'author': 'Cao', 'year': '2020', 'journal-title': 'New England Journal of Medicine', 'DOI': '10.1056/NEJMoa2001282'}, { 'key': '10.1016/j.ajg.2022.04.005_b0180', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1186/s12985-020-01412-z', 'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 ' 'treatment: a rapid systematic review and meta-analysis', 'volume': '17', 'author': 'Shrestha', 'year': '2020', 'journal-title': 'Virology Journal'}, { 'key': '10.1016/j.ajg.2022.04.005_b0185', 'doi-asserted-by': 'crossref', 'unstructured': 'Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, ' 'Egorova AN, et al. AVIFAVIR for Treatment of Patients With Moderate ' 'Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III ' 'Multicenter Randomized Clinical Trial. Clinical Infectious Diseases ' '2020.', 'DOI': '10.1093/cid/ciaa1176'}, { 'issue': '10', 'key': '10.1016/j.ajg.2022.04.005_b0190', 'doi-asserted-by': 'crossref', 'first-page': '1192', 'DOI': '10.1016/j.eng.2020.03.007', 'article-title': 'Experimental Treatment with Favipiravir for COVID-19: An Open-Label ' 'Control Study', 'volume': '6', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering'}, { 'issue': '2', 'key': '10.1016/j.ajg.2022.04.005_b0195', 'doi-asserted-by': 'crossref', 'first-page': '291', 'DOI': '10.1080/14787210.2021.1950532', 'article-title': 'Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of ' 'COVID-19 patients with pneumonia: a multicenter Egyptian study', 'volume': '20', 'author': 'El-Bendary', 'year': '2022', 'journal-title': 'Expert Review of Anti-infective Therapy'}, { 'issue': '12', 'key': '10.1016/j.ajg.2022.04.005_b0200', 'doi-asserted-by': 'crossref', 'first-page': '6895', 'DOI': '10.1073/pnas.111085598', 'article-title': 'RNA virus error catastrophe: direct molecular test by using ribavirin', 'volume': '98', 'author': 'Crotty', 'year': '2001', 'journal-title': 'Proceedings of the National Academy of Sciences'}, { 'key': '10.1016/j.ajg.2022.04.005_b0205', 'doi-asserted-by': 'crossref', 'first-page': 'e01348', 'DOI': '10.1128/JVI.01348-19', 'article-title': 'Small-molecule antiviral β-d-N 4-hydroxycytidine inhibits a ' 'proofreading-intact coronavirus with a high genetic barrier to ' 'resistance', 'volume': '93', 'author': 'Agostini', 'year': '2019', 'journal-title': 'Journal of virology'}, { 'issue': '7850', 'key': '10.1016/j.ajg.2022.04.005_b0210', 'doi-asserted-by': 'crossref', 'first-page': '451', 'DOI': '10.1038/s41586-021-03312-w', 'article-title': 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801', 'volume': '591', 'author': 'Wahl', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '10.1016/j.ajg.2022.04.005_b0215', 'doi-asserted-by': 'crossref', 'unstructured': 'Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et ' 'al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 ' 'in human airway epithelial cell cultures and multiple coronaviruses in ' 'mice. Science translational medicine 2020;12:eabb5883.', 'DOI': '10.1126/scitranslmed.abb5883'}, { 'issue': '6', 'key': '10.1016/j.ajg.2022.04.005_b0220', 'doi-asserted-by': 'crossref', 'first-page': '102329', 'DOI': '10.1016/j.dsx.2021.102329', 'article-title': 'Molnupiravir in COVID-19: a systematic review of literature', 'volume': '15', 'author': 'Singh', 'year': '2021', 'journal-title': 'Diabetes & Metabolic Syndrome: Clinical Research & Reviews'}, { 'key': '10.1016/j.ajg.2022.04.005_b0225', 'unstructured': "Pfizer. Pfizer's novel COVID‐19 oral antiviral treatment candidate " 'reduced risk of hospitalization or death by 89% in interim analysis of ' 'phase 2/3 EPIC‐HR study.'}], 'container-title': 'Arab Journal of Gastroenterology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1687197922000326?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1687197922000326?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 5, 6]], 'date-time': '2022-05-06T09:18:03Z', 'timestamp': 1651828683000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1687197922000326'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 5]]}, 'references-count': 45, 'alternative-id': ['S1687197922000326'], 'URL': 'http://dx.doi.org/10.1016/j.ajg.2022.04.005', 'relation': {}, 'ISSN': ['1687-1979'], 'subject': ['Gastroenterology'], 'container-title-short': 'Arab Journal of Gastroenterology', 'published': {'date-parts': [[2022, 5]]}}